Baxter Appoints James Saccaro as Treasurer and Corporate Officer

DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE:BAX) announced today that its Board of Directors has elected James K. Saccaro as treasurer and a corporate officer of the company.

Saccaro assumes the treasurer role from Robert J. Hombach, who was named the company’s chief financial officer in 2010. Most recently, Saccaro had served as vice president of strategy for Baxter. He joined the company in 2002 as manager of strategy for the company’s BioScience business, and over the years assumed positions of increasing responsibility, including vice president of financial planning, and vice president of finance for the company’s operations in Europe, Middle East and Africa. Prior to joining Baxter, he held strategy and business development positions at Clear Channel Communications and the Walt Disney Company. Saccaro received a bachelor’s degree in economics and master’s degree in Engineering-Economic Systems from Stanford University.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.



CONTACT:

Baxter International Inc.
Media Contacts:
Erin Gardiner, (847) 948-4210
Moyra Knight, (847) 948-3068
or
Investor Contacts:
Mary Kay Ladone, (847) 948-3371
Clare Trachtman, (847) 948-3085

KEYWORDS:   United States  North America  Illinois

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.